PFE — Pfizer Inc.

Pfizer Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Full Year 2025 Revenue: $62.6 billion, a 2% operational decline from $63.6 billion in 2024. Excluding COVID-19 products, operational revenue grew by 6%.
• Q4 2025 Revenue: $17.6 billion, down 3% operationally year-over-year, primarily due to a 40% decline in COVID product sales.
• Adjusted Diluted EPS: $3.22 for the full year, up from $3.11 in 2024; Q4 adjusted diluted EPS was $0.66, exceeding expectations.
• Adjusted Gross Margin: Expanded to 76% for the full year and approximately 71% for Q4.
• Shareholder Returns: $9.8 billion returned via dividends in 2025.

2. Strategic Updates and Business Highlights:

• Pfizer achieved 40 approvals and initiated 11 pivotal studies in 2025, enhancing its product pipeline.
• Key acquisitions (Seagen, Metaira, Biohaven) are expected to drive future growth, particularly in oncology and chronic weight management.
• The FDA approved PATCEV for bladder cancer, expanding the addressable patient population significantly.
• The company is focusing on advancing its obesity portfolio, particularly with the promising results from the VSPR III study of the ultra-long-acting GLP-1 receptor agonist, PF-3944.
• Pfizer is scaling AI across R&D, manufacturing, and commercial operations to enhance productivity and innovation.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $59.5 billion and $62.5 billion, with adjusted diluted EPS in the range of $2.80 to $3.00.
• Anticipated continued revenue decline from COVID products, projected at approximately $5 billion in 2026.
• Non-COVID product portfolio expected to grow operationally by about 4% year-over-year, despite anticipated revenue compression from generic entries.

4. Bad News, Challenges, or Points of Concern:

• The decline in COVID product revenues due to reduced demand and lower infection rates is a significant headwind.
• Pfizer faces a looming loss of exclusivity (LOE) for several key products between 2026 and 2028, which could impact future revenue.
• Approximately $4.4 billion in non-cash intangible asset impairments were recorded, reflecting strategic decisions to deprioritize certain products.
• Competitive pressures in the obesity and oncology markets, particularly with increasing competition in the GLP-1 space.

5. Notable Q&A Insights:

• VSPR III Data: The tolerability profile of PF-3944 appears favorable, with no significant increase in severe side effects when switching to monthly dosing. Full data will be presented at ADA in June.
• Market Potential: The obesity market is projected to be $150 billion, with significant opportunities in both US and international markets.
• Integration of Seagen: Integration efforts are progressing well, with multiple programs accelerated and new phase three studies planned.
• AI Investments: Pfizer is embedding AI across various functions to enhance productivity and reduce costs, with specific metrics being developed to measure success.
• Pipeline Differentiation: The company is exploring additional studies to differentiate its products in a crowded market, particularly in oncology.

Overall, Pfizer's performance in 2025 reflects strong execution despite challenges in the COVID product segment, with a clear focus on strategic growth areas and innovation as it navigates upcoming LOEs.